PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Breast Care - Switzerland
doi 10.1159/000453569
Full Text
Abstract

Available in full text

Categories
SurgeryOncology
Date
Authors
Publisher

S. Karger AG

Related search

Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer

Frontiers in Oncology
Cancer ResearchOncology
2020English

Oncolytic Virus and PD-1/PD-L1 Blockade Combination Therapy

Oncolytic Virotherapy
2018English

Analysis of Blimp-1 and PD-1/PD-L1 Immune Checkpoint in an Autoimmune Thyroiditis Animal Model

International Journal of Endocrinology
EndocrineEndocrinologyMetabolismAutonomic SystemsDiabetes
2020English

PD-1/PD-L1 Blockade: A New Promising Therapy for the Treatment of Pancreatic Cancer?

Pancreas - Open Journal
2018English

Pd-1 Immune Checkpoint Blockade Improves Anti-Cd20 Based Immunotherapy in Follicular Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Poor Outcome With Anti-Programmed Death-Ligand 1 (PD-L1) Antibody Due to Poor Pharmacokinetic Properties in PD-1/PD-L1 Blockade-Sensitive Mouse Models

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2020English

Direct Therapeutic Targeting of Immune Checkpoint PD-1 in Pancreatic Cancer

British Journal of Cancer
Cancer ResearchOncology
2018English

Crosslink Between Temozolomide and PD-L1 Immune-Checkpoint Inhibition in Glioblastoma Multiforme

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

Intratumoral Immune Cells Expressing PD-1/PD-L1 and Their Prognostic Implications in Cancer: A Meta-Analysis

International Journal of Biological Markers
OncologyCancer ResearchClinical BiochemistryForensic MedicineMedicinePathology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy